+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are studying nerandomilast as a potential treatment for adults with systemic sclerosis SSc, a condition that causes skin thickening and affects internal organs. This phase 3 trial aims to evaluate whether nerandomilast improves symptoms and slows disease progression in people with limited or diffuse cutaneous SSc who have had disease onset within 7 years of their first non-Raynauds symptom. The study is sponsored by Boehringer Ingelheim and compares nerandomilast to a placebo in a double-blind, randomized design. Participants are randomly assigned to one of two groups one group takes nerandomilast tablets and the other takes placebo tablets. Both types of tablets are film-coated and look the same. Participants take these tablets twice daily. The study lasts from 1 to about 4 years, during which participants attend regular visits and receive phone calls from study staff. The trial includes adults with active disease who may be untreated or on stable immunosuppressive treatments. During the study, participants undergo repeated assessments including blood tests and evaluations of skin thickening, lung function, and overall health. Doctors also monitor internal organs and check for any side effects or safety concerns related to the treatment. The main outcome measured is the time until disease progression or death over up to 4 years. Other outcomes include changes in skin score, lung function, and quality of life. Safety and tolerability are closely monitored throughout the study period.

Age: 18Years +All GendersPhase 3
248 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the nutritional status, body composition, dietary intakes, and related biochemical and clinical parameters of Filipino pediatric patients diagnosed with Inborn Errors of Intermediary Protein Metabolism IEIPM. This includes amino acid disorders, organic acidemias, and urea cycle defects. The study aims to better understand the nutritional challenges faced by children from newborn to 18 years old with IEIPM, as well as the caregivers experiences managing these conditions under special dietary needs. This research supports the development of tailored nutrition policies and programs in the Philippines for this rare disease population. Participants include pediatric patients diagnosed with IEIPM who are receiving medical and dietary treatment, along with age- and sex-matched healthy children as controls. The study compares nutritional status, body composition, dietary intake, and clinical indicators at baseline, 6 months, and 12 months. Data on natural and medical food consumption, protein-energy ratios, and biochemical markers will be collected to assess adequacy and associations with growth and health outcomes. During the 12-month study, participants will undergo evaluations of weight, heightlength, head circumference, fat and lean mass, bone mineral density, and dietary intake at specified intervals. Blood samples will be analyzed for amino acid levels, vitamins, minerals, and anemia risk. Caregivers will also provide information about dietary management experiences. This comprehensive assessment aims to guide improved nutritional care and support for pediatric IEIPM patients in the local healthcare setting.

Age: 0Months - 18YearsAll Genders
14 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
P

Actively Recruiting

Researchers are evaluating the safety and tolerability of trastuzumab deruxtecan T-DXd combined with immunotherapy agents, with or without chemotherapy, in patients who have HER2 over-expressing non-small cell lung cancer NSCLC. This phase Ib study focuses on advanced or metastatic non-squamous NSCLC patients, aiming to understand optimal dosing and safety profiles. The study is sponsored by AstraZeneca and includes multiple study parts to explore different drug combinations and regimens. The trial includes several parts Part 1 involved dose escalation of T-DXd with durvalumab plus cisplatin, carboplatin, or pemetrexed Parts 3, 4, and 5 assess combinations of T-DXd with volrustomig or rilvegostomig, with or without carboplatin, in various dosing schedules. Patients receive the study drugs as intravenous infusions. Some parts involve randomization between arms with or without carboplatin, focusing on dose optimization in first-line treatment settings. Enrollment in some parts is closed, while others continue to explore safety and efficacy. Participants undergo regular assessments including tumor measurements by RECIST 1.1, organ and bone marrow function tests, and monitoring of adverse events for about 20 months. The study measures safety outcomes like frequency of adverse events and serious adverse events, and secondary outcomes such as response rate, duration of response, disease control, progression-free survival, overall survival, and pharmacokinetics of the drugs. Immunogenicity of the treatments is also evaluated. Participants must have measurable disease and meet performance status criteria, with follow-up to assess treatment effects and safety.

Age: 18Years +All GendersPhase 1
91 locations
E

Actively Recruiting

Researchers are conducting a Phase III international study to evaluate the effects of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in patients with chronic heart failure HF and impaired kidney function who have recently experienced a heart failure event. The study aims to assess the impact of these treatments on cardiovascular death and heart failure events, including hospitalizations and other HF-related episodes. Participants are randomly assigned to one of three groups one receiving balcinrenonedapagliflozin 15 mg10 mg capsule plus placebo another receiving balcinrenonedapagliflozin 40 mg10 mg capsule plus placebo and a third group receiving dapagliflozin 10 mg tablet plus placebo capsule. All treatments are given once daily orally, alongside standard care for heart failure and kidney impairment. The study is conducted across approximately 700 sites in about 40 countries. During the trial, participants will be monitored over approximately 36 months for cardiovascular death, heart failure hospitalizations, and heart failure events without hospitalization. Assessments include heart failure symptom scores measured at 24 weeks post-randomization. Researchers will also track total occurrences of cardiovascular and heart failure events, as well as overall mortality. This long-term follow-up aims to evaluate treatment effects on these important health outcomes.

Age: 18Years - 130YearsAll GendersPhase 3
852 locations